AstraZeneca (NYSE:AZN) announced new study data on SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR) for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients. The results from the studies were presented today at the 161st Annual Meeting of the American Psychiatric Association (APA) in Washington, DC.
Popularity: unranked [?]
Related posts:
- New Study Results Provide Additional Data About Short- And Long-Term Use Of Desvenlafaxine Succinate In The Treatment Of Major Depressive Disorder
- Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement In Symptoms Of Depression In Adult Patients Versus Placebo
- Deep Brain Stimulation For Depression Pilot Study Demonstrates Sustained Improvement In Depression Symptoms
- Patients In St. Jude Medical Deep Brain Stimulation For Depression Pilot Study Demonstrate Sustained Improvement In Depression Symptoms
- Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms In Adolescents
Comments
No Responses to “Seroquel Evaluation On Improvement In Short And Long-Term Symptoms”